Prot #SGN22E-003: An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab with or without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date9/14/209/14/23

Funding

  • Seattle Genetics, Inc. (Prot #SGN22E-003)